WPA
PTCT icon

West Paces Advisors’s PTC Therapeutics PTCT Stock Holding History

West Paces Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$10.2K – 473
2025
Q1 		$10.2K Sell
200
-300
-60% -$15K ﹤0.01% 346
2024
Q4 		$22.6K Hold
500
– – 0.01% 294
2024
Q3 		$18.6K Hold
500
– – ﹤0.01% 307
2024
Q2 		$15.3K Sell
500
-500
-50% -$16.2K ﹤0.01% 314
2024
Q1 		$29.1K Hold
1,000
– – 0.01% 279
2023
Q4 		$27.6K Hold
1,000
– – 0.01% 275
2023
Q3 		$22.4K Buy
+1,000
New +$37.2K 0.01% 285

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

West Paces Advisors's PTCT Position: Q2 2025 in Review

West Paces Advisors sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 200 shares — an estimated $10.2K sold.

West Paces Advisors first reported a position in PTCT in Q3 2023 and held it in 7 quarters. The position peaked at $29.1K in Q1 2024. 283 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • West Paces Advisors reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • West Paces Advisors sold 200 PTC Therapeutics shares in Q2 2025, an estimated $10.2K.
  • West Paces Advisors first reported a position in PTC Therapeutics in Q3 2023 and held it in 7 quarters.
  • West Paces Advisors's PTC Therapeutics position peaked at $29.1K in Q1 2024.
  • 283 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on West Paces Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.